Levobupivacaine, the S-enantiomer of racemic bupivacaine, was developed in response to concerns regarding the cardiotoxic and neurotoxic potential of its parent compound, particularly following inadvertent intravascular injection (Foster & Markham, 2000). Preclinical work established that the toxicity of bupivacaine is enantioselective, with the R-isomer (dexbupivacaine) being responsible for the majority of adverse cardiovascular effects, while the S-isomer retains comparable anesthetic potency with a more favorable safety margin (Bajwa & Kaur, 2013).
Pharmacokinetically, levobupivacaine is highly protein-bound (approximately 97%, compared with 95% for racemic bupivacaine), a property attributed to its faster protein-binding rate and thought to contribute to its reduced systemic toxicity (Bajwa & Kaur, 2013). It is extensively metabolized by hepatic cytochrome P450 isoforms CYP1A2 and CYP3A4, without evidence of metabolic inversion to the R-form either in vitro or in vivo (Foster & Markham, 2000).
In terms of anesthetic efficacy, levobupivacaine demonstrates potency essentially equivalent to bupivacaine across epidural, intrathecal, and peripheral nerve block techniques, with onset of action generally within 15 minutes (Foster & Markham, 2000). Clinical trials have consistently shown a modest but reproducible trend toward longer sensory block duration with levobupivacaine relative to bupivacaine at equivalent doses, while producing comparatively less dense motor blockade following epidural administration—a differential considered advantageous for labor analgesia and postoperative rehabilitation (Foster & Markham, 2000; Bajwa & Kaur, 2013).
The comparison with ropivacaine, another enantiomerically pure long-acting local anesthetic, remains a clinical question of interest. A meta-analysis of twelve randomized controlled trials in peripheral nerve block found no significant differences between the two agents in onset times or motor block duration but reported that levobupivacaine provided significantly longer overall block duration and a lower incidence of postoperative rescue analgesia requirements (Li et al., 2017). A trend toward longer sensory block duration with levobupivacaine was also observed, though considerable heterogeneity across studies limits the strength of these conclusions (Li et al., 2017).
The principal advantage of levobupivacaine lies in its reduced potential for cardiac and central nervous system toxicity relative to racemic bupivacaine. Human volunteer studies have demonstrated a lesser negative inotropic effect, reduced QTc prolongation at higher intravenous doses, and a lower incidence of central or peripheral nervous system disturbances with levobupivacaine (Foster & Markham, 2000). The safety margin—defined as the concentration increase required before toxicity manifests—is reported as being approximately 1.3 times greater than that of racemic bupivacaine (Bajwa & Kaur, 2013). Case reports of inadvertent intravascular administration have generally described successful resuscitation with supportive measures, and in some instances, intravenous lipid emulsion therapy (Bajwa & Kaur, 2013).
Clinically, levobupivacaine has found broad application across surgical anesthesia, labor analgesia, and postoperative pain management, with adjunctive agents such as fentanyl, morphine, and clonidine commonly used to potentiate its effect while sparing total dose requirements (Bajwa & Kaur, 2013). As with all amide local anesthetics, careful attention to dosing and injection accuracy remains essential to minimize the risk of systemic toxicity.
References
- Bajwa, S. J. S., & Kaur, J. (2013). Clinical profile of levobupivacaine in regional anesthesia: A systematic review. Journal of Anaesthesiology Clinical Pharmacology, 29(4), 530–539. https://doi.org/10.4103/0970-9185.119172
- Foster, R. H., & Markham, A. (2000). Levobupivacaine: A review of its pharmacology and use as a local anaesthetic. Drugs, 59(3), 551–579. https://doi.org/10.2165/00003495-200059030-00013
- Li, A., Wei, Z., Liu, Y., Shi, J., Ding, H., Tang, H., Zheng, P., Gao, Y., & Feng, S. (2017). Ropivacaine versus levobupivacaine in peripheral nerve block: A PRISMA-compliant meta-analysis of randomized controlled trials. Medicine, 96(14), e6551. https://doi.org/10.1097/MD.0000000000006551